Back to top
more

Better trading starts here.

Brokerage Reports

Research for REGN

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

3 items in cart

View Cart/Checkout

Regeneron Pharmaceuticals, Inc. [REGN]

Reports for Purchase

Showing records 561 - 580 ( 593 total )

Company: Regeneron Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 561

05/09/2012

Company Report

Pages: 6

Arcalyst FDA Panel: Unanimous Against; Street Shrugs

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Regeneron Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 562

05/08/2012

Company Report

Pages: 4

Strengthened Commercial Profile for Eylea in Japan

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 10.00

Research Provided by a Third Party

Company: Regeneron Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 563

05/08/2012

Daily Note

Pages: 16

MORNING CALL SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 50.00

Research Provided by a Third Party

Company: Regeneron Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 564

04/30/2012

Company Report

Pages: 4

CATT 2-Year Data; The Push and Pull of Eylea > Lucentis

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 10.00

Research Provided by a Third Party

Company: Regeneron Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 565

04/30/2012

Company Report

Pages: 7

Price: 24.95

Company: Regeneron Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 566

04/27/2012

Daily Note

Pages: 23

MORNING CALL SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 75.00

Research Provided by a Third Party

Company: Regeneron Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 567

04/26/2012

Company Report

Pages: 8

1Q12 Results; So Long Biotech, Hello Pharma Status; Target to $115

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Regeneron Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 568

04/12/2012

Company Report

Pages: 12

Griffin Securities Updates Coverage on Lpath, Inc. (LPTN)

Provider: GRIFFIN SECURITIES, INC.

Analyst: MARKEY K

Price: 25.00

Research Provided by a Third Party

Company: Regeneron Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 569

04/05/2012

Daily Note

Pages: 10

MORNING CALL SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 25.00

Research Provided by a Third Party

Company: Regeneron Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 570

04/05/2012

Daily Note

Pages: 6

No Surprises on Zaltrap Announcements; Target to $105, Maintain Neutral

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Regeneron Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 571

03/27/2012

Daily Note

Pages: 11

MORNING CALL SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 25.00

Research Provided by a Third Party

Company: Regeneron Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 572

03/26/2012

Company Report

Pages: 8

''727 Gets Its Spotlight Moment at ACC

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Regeneron Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 573

03/08/2012

Company Report

Pages: 4

EYLEA Approved in Australia

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 10.00

Research Provided by a Third Party

Company: Regeneron Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 574

03/08/2012

Daily Note

Pages: 18

MORNING CALL SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 50.00

Research Provided by a Third Party

Company: Regeneron Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 575

02/28/2012

Daily Note

Pages: 14

MORNING CALL SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 50.00

Research Provided by a Third Party

Company: Regeneron Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 576

02/27/2012

Company Report

Pages: 6

VENICE Phase III Preview; Not So Confident After String of Successes

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Regeneron Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 577

02/21/2012

Company Report

Pages: 8

Price: 24.95

Company: Regeneron Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 578

02/14/2012

Daily Note

Pages: 11

MORNING CALL SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 25.00

Research Provided by a Third Party

Company: Regeneron Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 579

02/14/2012

Company Report

Pages: 8

2011 Results; Eylea Wow Factor Continues

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Regeneron Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 580

01/17/2012

Company Report

Pages: 8

Price: 24.95